Fentanyl deaths in the United States peaked at roughly 75,000 in 2023. The 2024 number was about 64,000, and provisional CDC data for 2025 puts it at approximately 52,000. That is a real decline. It is also a number that, if it were caused by anything other than drugs, would be considered a national emergency without parallel. Fentanyl overdose remains the leading cause of death for Americans between the ages of 18 and 45. The drug is, almost exclusively, manufactured by Mexican cartels using precursor chemicals shipped from China and pressed into pills or mixed into other substances before crossing into the United States.
The reporting on what is bringing the number down comes from a mix of sources including the DEA, the CDC, academic researchers, and outlets like the AP, ProPublica, and the Washington Post. Three factors keep coming up. First, the rapid expansion of naloxone availability has saved tens of thousands of lives. Naloxone, the overdose reversal drug, is now sold over the counter, distributed free in many states, and carried by police, EMTs, and increasingly by ordinary people in affected communities. Second, the supply of carfentanil and other ultra-potent synthetics has actually softened slightly as Chinese export controls have tightened under bilateral pressure from the Biden and current administrations. Third, the population of people most at risk of overdose has, tragically, contracted, as the heaviest users from the early waves of the epidemic have either died or entered recovery.
The harder finding is what has not been working. Major drug seizures at the border, while increasing in volume, do not appear to be the primary driver of the decline. CBP seized more than 27,000 pounds of fentanyl in 2024, the highest figure on record, almost all of it at legal ports of entry hidden in vehicles and commercial cargo. That suggests the cartels are producing far more than seizures intercept, and that the bottleneck on overdoses is more about demand-side factors like naloxone and overdose response than about supply-side interdiction. The wall, whatever you think of it as policy, is not relevant to fentanyl flow because the drug does not come across the open desert. It comes through legal ports inside cars.
The treatment side of the question is where this country has historically been least serious. Medication-assisted treatment with buprenorphine and methadone is the single most evidence-based intervention for opioid addiction. The science on it is not contested. Most of the West, including conservative-governed places like Britain and France, treats opioid addiction with extensive use of these medications and gets better outcomes than we do. The US has steadily expanded access, particularly after federal rules were loosened in 2023 and 2024, but coverage remains uneven and rural treatment access is poor. A working family in eastern Kentucky or southern Ohio whose teenager needs medication-assisted treatment may have to drive an hour and find a provider who is taking new patients. That is not a policy failure that can be blamed on Mexico.
If we are going to be serious as a country about the cartels, and most of us across the political spectrum want to be, the data points in two directions. First, the diplomatic pressure on China to control fentanyl precursors has worked when it has been applied; it should be continued and tightened. Second, the meaningful gains on the death toll have come from making naloxone and treatment widely available in our own communities, not from the border. Tough talk about military strikes in Mexico polls well and produces little. Naloxone in every gas station and police cruiser, and medication-assisted treatment in every county, produces a number that goes down. The cartels are an enemy. Treating Americans who got hooked as our own people, not as criminals, is how we beat them.